Skip to content
drillr.ai
Sign up

CRDL

Cardiol Therapeutics, Inc.

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA

Also listed · CRDL.CA →
$1.10
+0.00%
Ask drillr

  • Sep 23, 2026, 10:00 UTC

    Cardiol Therapeutics achieved its Phase III MAVERIC enrollment target of 110 patients ahead of schedule and expanded the pivotal trial of CardiolRx™ to up to 150 patients.

    Source:

  • Sep 16, 2026, 11:27 UTC

    Cardiol Therapeutics announced the exercise of warrants for over USD 7 million in proceeds, strengthening its balance sheet ahead of Phase III MAVERIC trial data in recurrent pericarditis.

    Source:

  • Sep 10, 2026, 21:00 UTC

    Cardiol Therapeutics filed a preliminary short form base shelf prospectus for up to US$150 million with Canadian securities regulators and a corresponding Form F-10 registration statement with the US SEC.

    Source: